Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Malte Knöll, Rashmi Priyadharshini Dheenadayalan, Deyan Y. Yosifov, Jialei Qi, Christof Schneider, Felix Seyfried, Lueder Hinrich Meyer, Paula Cramer, Julia Von Tresckow, Michael Hallek, Barbara F. Eichhorst, Eugen Tausch, Stephan Stilgenbauer, Billy Jebaraj

Blood (2024) 144 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2024-204910

Published: 2024

Journal Articles

Inhibition of Cyclin-Dependent Kinase 9 Rapidly Induces Apoptosis in Acute Lymphoblastic Leukemia and Shows Synergistic Activity with BH3-Mimetics

Colin Fortner, Alexandra Niedermayer, Stefanie Enzenmüller, Klaus-Michael Debatin, Felix Seyfried, Lüder Hinrich Meyer

Blood (2024) 144 (Supplement 1): 2835.

https://doi.org/10.1182/blood-2024-208375

Published: 2024

Journal Articles

Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia

Colin Fortner, Maren Wichert, Alexandra Niedermayer, Klaus-Michael Debatin, Lüder Hinrich Meyer, Felix Seyfried

Blood (2023) 142 (Supplement 1): 1608.

https://doi.org/10.1182/blood-2023-177613

Published: 2023

Journal Articles

Acquired Venetoclax Resistance in an In Vivo Model of B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Altered Functions of Apoptosis Regulators

Stefanie Enzenmüller, Alexandra Niedermayer, Felix Seyfried, Alexander Groß, Klaus-Michael Debatin, Lüder Hinrich Meyer

Blood (2023) 142 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2023-185621

Published: 2023

Journal Articles

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Billy Jebaraj, Rashmi Priyadharshini Dheenadayalan, Annika Müller, Jialei Qi, Eugen Tausch, Christof Schneider, Daniela Steinbrecher, Daniel Mertens, Felix Seyfried, Lüder Hinrich Meyer, André Lechel, Barbara F. Eichhorst, Courtney L Andersen, Giulia Fabbri, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 84.

https://doi.org/10.1182/blood-2023-188554

Published: 2023

Journal Articles

Venetoclax Resistance in B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Increased Mitochondrial Metabolism and Can be Overcome By Co-Targeting Oxidative Phosphorylation

Alexandra Niedermayer, Stefanie Enzenmüller, Felix Seyfried, Daniel Tews, Pamela Fischer-Posovszky, Ulrich Rupp, Paul Walther, Klaus-Michael Debatin, Lüder Hinrich Meyer

Blood (2022) 140 (Supplement 1): 6358–6359.

https://doi.org/10.1182/blood-2022-166223

Published: 2022

Journal Articles

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Scheffold, Felix Seyfried, Lüder Meyer, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Stephan Stilgenbauer, Billy Michael Chelliah Jebaraj

Blood (2022) 140 (Supplement 1): 3139–3141.

https://doi.org/10.1182/blood-2022-159427

Published: 2022

Journal Articles

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M. Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A. Fox, Klaus-Michael Debatin, Lüder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer

Blood (2022) 139 (6): 859–875.

https://doi.org/10.1182/blood.2021011516

Published: 2022

Includes: Supplemental data

Journal Articles

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (20): 1953–1965.

https://doi.org/10.1182/blood.2020007591

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic Activity of BH3-Mimetics By Combined Targeting of Anti-Apoptotic Regulators in B-Cell Precursor ALL

Felix Seyfried, Felix Stirnweiß, Alexandra Niedermayer, Stefanie Enzenmüller, Rebecca Hörl, Stefan Köhrer, Klaus-Michael Debatin, Lüder Hinrich Meyer

Blood (2021) 138 (Supplement 1): 706.

https://doi.org/10.1182/blood-2021-150162

Published: 2021

Journal Articles

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Alexandra Niedermayer, MSc, Stefanie Enzenmüller, PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Felix Seyfried, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2019) 134 (Supplement_1): 3954.

https://doi.org/10.1182/blood-2019-126582

Published: 2019

Journal Articles

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Daniela Steinbrecher, PhD, Felix Seyfried, MD, Eugen Tausch, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Christof Schneider, MD

Blood (2019) 134 (Supplement_1): 1507.

https://doi.org/10.1182/blood-2019-127931

Published: 2019

Journal Articles

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Daniela Steinbrecher, MSc, Felix Seyfried, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Christof Schneider, MD

Blood (2018) 132 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2018-99-115845

Published: 2018

Journal Articles

Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Felix Seyfried, Felix Stirnweiß, Stefan Köhrer, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2018) 132 (Supplement 1): 1416.

https://doi.org/10.1182/blood-2018-99-117139

Published: 2018

Journal Articles

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia

Ameera Alsadeq, Lennart Lenk, Anila Vadakumchery, Antony Cousins, Christian Vokuhl, Ahmad Khadour, Fotini Vogiatzi, Felix Seyfried, Lueder-Hinrich Meyer, Gunnar Cario, Elias Hobeika, Klaus-Michael Debatin, Christina Halsey, Martin Schrappe, Denis M. Schewe, Hassan Jumaa

Blood (2018) 132 (15): 1614–1617.

https://doi.org/10.1182/blood-2018-04-844209

Published: 2018

Includes: Supplemental data

Journal Articles

Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia

Fan Wang, Salih Demir, Franziska Gehringer, Clarissa D. Osswald, Felix Seyfried, Stefanie Enzenmüller, Sarah M. Eckhoff, Thomas Maier, Karlheinz Holzmann, Klaus-Michael Debatin, Thomas Wirth, Lüder H. Meyer, Alexey Ushmorov

Blood (2018) 131 (26): 2929–2942.

https://doi.org/10.1182/blood-2017-10-813576

Published: 2018

Includes: Supplemental data

Journal Articles

Targeting of the Interleukin-7 Receptor Alpha-Chain (IL-7Rα) Blocks B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Development and Reduces Leukemic Infiltration to the Central Nervous System (CNS)

Ameera Alsadeq, PhD, Anila George Vadakumchery, Ali Almasri, Hend Abdelrasoul, Markus Werner, PhD, Lennart Lenk, Felix Seyfried, Klaus-Michael Debatin, MD, Lueder-Hinrich Myer, MD, Gunnar Cario, MD, Martin Schrappe, MD PhD, Denis Martin Schewe, MD, Hassan Jumaa, PhD

Blood (2017) 130 (Supplement 1): 479.

https://doi.org/10.1182/blood.V130.Suppl_1.479.479

Published: 2017

Journal Articles

Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor

Vera Münch, Luca Trentin, Julia Herzig, Salih Demir, Felix Seyfried, Johann M. Kraus, Hans A. Kestler, Rolf Köhler, Thomas F. E. Barth, Geertruy te Kronnie, Klaus-Michael Debatin, Lüder H. Meyer

Blood (2017) 130 (5): 643–654.

https://doi.org/10.1182/blood-2017-03-769315

Published: 2017

Includes: Supplemental data

Journal Articles

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

Felix Seyfried, MD, Salih Demir, MSc, Rebecca Hörl, Stefan Köhrer, Annika Scheffold, Stephan Stilgenbauer, Klaus-Michael Debatin, MD PhD, Lüder Hinrich Meyer, MD

Blood (2016) 128 (22): 1081.

https://doi.org/10.1182/blood.V128.22.1081.1081

Published: 2016

Journal Articles

Synergistic Activity of ABT-199 with Conventional Chemotherapy and Dinaciclib in B-Cell Precursor Acute Lymphoblastic Leukemia

Felix Seyfried, Salih Demir, MSc, Klaus-Michael Debatin, MDPhD, Lueder Hinrich Meyer, MD

Blood (2015) 126 (23): 2631.

https://doi.org/10.1182/blood.V126.23.2631.2631

Published: 2015

NARROW

Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Inhibition of Cyclin-Dependent Kinase 9 Rapidly Induces Apoptosis in Acute Lymphoblastic Leukemia and Shows Synergistic Activity with BH3-Mimetics

Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia

Acquired Venetoclax Resistance in an In Vivo Model of B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Altered Functions of Apoptosis Regulators

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Venetoclax Resistance in B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Increased Mitochondrial Metabolism and Can be Overcome By Co-Targeting Oxidative Phosphorylation

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Synergistic Activity of BH3-Mimetics By Combined Targeting of Anti-Apoptotic Regulators in B-Cell Precursor ALL

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia

Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia

Targeting of the Interleukin-7 Receptor Alpha-Chain (IL-7Rα) Blocks B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Development and Reduces Leukemic Infiltration to the Central Nervous System (CNS)

Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

Synergistic Activity of ABT-199 with Conventional Chemotherapy and Dinaciclib in B-Cell Precursor Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only